Literature DB >> 29315555

Autoimmunity and autoimmune co-morbidities in psoriasis.

Kazuhisa Furue1, Takamichi Ito1, Gaku Tsuji1, Takafumi Kadono2, Takeshi Nakahara1,3, Masutaka Furue1,3.   

Abstract

Psoriasis is characterized by widespread scaly erythematous plaques that cause significant physical and psychological burdens for the affected individuals. Accelerated inflammation driven by the tumour necrosis factor-α/interleukin-23/interleukin-17 axis is now known to be the major mechanism in the development of psoriasis. In addition, psoriasis has an autoimmune nature that manifests as autoreactive T cells and is co-morbid with other autoimmune diseases, such as autoimmune bullous diseases, vitiligo, alopecia and thyroiditis. In this article, we review the recent topics on autoimmunity and autoimmune co-morbidities in psoriasis.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  alopecia; autoimmunity; bullous pemphigoid; psoriasis; thyroiditis; vitiligo

Mesh：

Substances：

Year:  2018        PMID： 29315555      PMCID： PMC5904708          DOI： 10.1111/imm.12891

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


  148 in total

1.  Association of psoriasis with Hashimoto's thyroiditis, Sjögren's syndrome and dermatomyositis.

Authors:  Michiko Akiyama; Takashi Ueno; Akiko Kanzaki; Masataka Kuwana; Mototsugu Nagao; Hidehisa Saeki
Journal:  J Dermatol       Date:  2016-01-18       Impact factor: 4.005

2.  Economic burden of psoriatic patients in Japan: Analysis from a single outpatient clinic.

Authors:  Hidetoshi Takahashi; Katsuhiko Satoh; Akiyoshi Takagi; Hajime Iizuka
Journal:  J Dermatol       Date:  2017-04-13       Impact factor: 4.005

Review 3.  Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment.

Authors:  Emma Guttman-Yassky; James G Krueger; Mark G Lebwohl
Journal:  Exp Dermatol       Date:  2017-05-09       Impact factor: 3.960

4.  Drug concentration and antidrug antibodies in patients with psoriasis treated with adalimumab or etanercept.

Authors:  M Gyldenløve; C Zachariae; P Jensen; H Griehsel; M Ståhle; L Skov
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-07-03       Impact factor: 6.166

5.  Dermoscopy in differential diagnosis of palmar psoriasis and chronic hand eczema.

Authors:  Enzo Errichetti; Giuseppe Stinco
Journal:  J Dermatol       Date:  2015-10-13       Impact factor: 4.005

6.  Certolizumab pegol, a pegylated anti-TNF-α antagonist, caused de novo-onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis.

Authors:  Haruka Koizumi; Atsushi Tokuriki; Noritaka Oyama; Hideki Ido; Kazumitsu Sugiura; Masashi Akiyama; Minoru Hasegawa
Journal:  J Dermatol       Date:  2016-09-07       Impact factor: 4.005

7.  Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis.

Authors:  Dae Suk Kim; Dongyun Shin; Min Seok Lee; Hee Ju Kim; Do Young Kim; Soo Min Kim; Min-Geol Lee
Journal:  J Dermatol       Date:  2015-08-18       Impact factor: 4.005

8.  IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms.

Authors:  Hye-Lin Ha; Hongshan Wang; Prapaporn Pisitkun; Jin-Chul Kim; Ilaria Tassi; Wanhu Tang; Maria I Morasso; Mark C Udey; Ulrich Siebenlist
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

9.  Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.

Authors:  Paula Dávila-Seijo; Esteban Dauden; M A Descalzo; Gregorio Carretero; José-Manuel Carrascosa; Francisco Vanaclocha; Francisco-José Gómez-García; Pablo De la Cueva-Dobao; Enrique Herrera-Ceballos; Isabel Belinchón; José-Luis López-Estebaranz; Merce Alsina; José-Luis Sánchez-Carazo; Marta Ferrán; Rosa Torrado; Carlos Ferrandiz; Raquel Rivera; Mar Llamas; Rafael Jiménez-Puya; Ignacio García-Doval
Journal:  J Invest Dermatol       Date:  2016-09-25       Impact factor: 8.551

10.  Psoriasis and cardiometabolic traits: modest association but distinct genetic architectures.

Authors:  Manja Koch; Hansjörg Baurecht; Janina S Ried; Elke Rodriguez; Sabrina Schlesinger; Natalie Volks; Christian Gieger; Ina-Maria Rückert; Luise Heinrich; Christina Willenborg; Catherine Smith; Annette Peters; Barbara Thorand; Wolfgang Koenig; Claudia Lamina; Henning Jansen; Florian Kronenberg; Jochen Seissler; Joachim Thiery; Wolfgang Rathmann; Heribert Schunkert; Jeanette Erdmann; Jonathan Barker; Rajan P Nair; Lam C Tsoi; James T Elder; Ulrich Mrowietz; Michael Weichenthal; Sören Mucha; Stefan Schreiber; Andre Franke; Jochen Schmitt; Wolfgang Lieb; Stephan Weidinger
Journal:  J Invest Dermatol       Date:  2015-01-19       Impact factor: 8.551
View more
  16 in total

1.  Metformin inhibits IL-1β secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis.

Authors:  Gaku Tsuji; Akiko Hashimoto-Hachiya; Vu Hai Yen; Masaki Takemura; Ayako Yumine; Kazuhisa Furue; Masutaka Furue; Takeshi Nakahara
Journal:  Cell Death Discov       Date:  2020-03-04

2.  T cells and cytokines in inflamed psoriatic skin. Who's in charge?

Authors:  Simon Milling; Stefan Siebert
Journal:  Immunology       Date:  2020-08       Impact factor: 7.397

3.  High-frequency ultrasonography of psoriatic skin: A non-invasive technique in the evaluation of the entire skin of patients with psoriasis: A pilot study.

Authors:  Mihaela Cristina Șomlea; Andreea Nicoleta Boca; Alexandra Dana Pop; Roxana Flavia Ilieș; Stefan Cristian Vesa; Anca Dana Buzoianu; Alexandru Tătaru
Journal:  Exp Ther Med       Date:  2019-10-29       Impact factor: 2.447

4.  Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment.

Authors:  Muskaan Sachdeva; Asfandyar Mufti; Khalad Maliyar; Yuliya Lytvyn; Jensen Yeung
Journal:  J Am Acad Dermatol       Date:  2020-05-19       Impact factor: 11.527

5.  Interstitial Pneumonia in Psoriasis.

Authors:  Hironori Kawamoto; Hiromichi Hara; Shunsuke Minagawa; Takanori Numata; Jun Araya; Yumi Kaneko; Yoshinori Umezawa; Akihiko Asahina; Hidemi Nakagawa; Kazuyoshi Kuwano
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2018-09-20

Review 6.  Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders.

Authors:  Michael P Schön
Journal:  Front Immunol       Date:  2019-07-26       Impact factor: 7.561

Review 7.  The contribution of IL-17 to the development of autoimmunity in psoriasis.

Authors:  Masutaka Furue; Takafumi Kadono
Journal:  Innate Immun       Date:  2019-05-24       Impact factor: 2.680

Review 8.  Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis.

Authors:  Masutaka Furue; Akiko Hashimoto-Hachiya; Gaku Tsuji
Journal:  Int J Mol Sci       Date:  2019-10-31       Impact factor: 5.923

Review 9.  Psoriasis and Co-morbidity.

Authors:  Mina Amin; Erica B Lee; Tsen-Fang Tsai; Jashin J Wu
Journal:  Acta Derm Venereol       Date:  2020-01-30       Impact factor: 3.875

10.  Increased Risk of Pemphigus among Patients with Psoriasis: A Large-scale Cohort Study.

Authors:  Khalaf Kridin; Ralf J Ludwig; Giovanni Damiani; Arnon D Cohen
Journal:  Acta Derm Venereol       Date:  2020-10-20       Impact factor: 3.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.